Physician profile
Dipti Patel
NPI 1134447667
$1,898.09
in general payments reported to CMS, 2019-2025
22 companies · $554 in 2025
The $554 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120 · 2020: $168 · 2021: $76.06 · 2022: $256 · 2023: $302 · 2024: $421 · 2025: $554.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,247 · Education: $30.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,247.05 |
| Education | $30.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $277.49 | 2022-2025 | Tarpeyo |
| Amgen INC. | $194.35 | 2019-2025 | Tavneos |
| Travere Therapeutics, INC. | $174.27 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $167.24 | 2020-2025 | Lokelma, Farxiga |
| Mallinckrodt Hospital Products INC. | $107.47 | 2024 | Acthar |
| Novartis Pharmaceuticals Corporation | $104.78 | 2025 | |
| Akebia Therapeutics INC | $100.41 | 2019-2024 | Vafseo |
| Melinta Therapeutics, LLC | $94.18 | 2022-2024 | Rezzayo, Kimyrsa |
| Vifor Pharma, INC. | $91.24 | 2019-2025 | Veltassa |
| Aurinia Pharma U.S., INC. | $86.38 | 2023-2025 | Lupkynis |
| Fresenius USA Marketing, INC. | $84.61 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $83.35 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $62.09 | 2022-2024 | Jynarque |
| Horizon Therapeutics Plc | $61.51 | 2022-2023 | Krystexxa |
| Ardelyx, INC. | $42.21 | 2024-2025 | Ibsrela |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $37.44 | 2022-2024 | Benlysta |
| Ani Pharmaceuticals, INC. | $27.15 | 2022 | |
| Sanofi-Aventis U.S. LLC | $25.00 | 2020 | |
| Bard Peripheral Vascular, INC. | $22.74 | 2021 | |
| Abbvie INC. | $21.25 | 2022 | |
| Genzyme Corporation | $18.96 | 2019 | |
| Lundbeck LLC | $13.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dipti Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.